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Version Code
The definition of the version code can be found at www.cap.org/cancerprotocols. Version: UvealMelanoma 3.3.0.0
Summary of Changes
The following changes have been made since the October 2013 release. : Tumor limited to the iris not more than 3 clock hours in size ___ pT1b: Tumor limited to the iris more than 3 clock hours in size ___ pT1c: Tumor limited to the iris with secondary glaucoma ___ pT2: Tumor confluent with or extending into the ciliary body, choroid, or both ___ pT2a: Tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma ___ pT3: Tumor confluent with or extending into the ciliary body, choroid, or both, with scleral extension ___ pT3a: Tumor confluent with or extending into the ciliary body, choroid, or both, with scleral extension and secondary glaucoma pT4: Tumor with extrascleral extension ___ pT4a: Tumor with extrascleral extension less than or equal to 5 mm in diameter ___ pT4b: Tumor with extrascleral extension more than 5 mm in diameter Ciliary Body and Choroid ___ pTX: Primary tumor cannot be assessed ___ pT0: No evidence of primary tumor pT1:Tumor size category 1 ___ pT1a: Tumor size category 1 without ciliary body involvement and extraocular extension ___ pT1b: Tumor size category 1 with ciliary body involvement ___ pT1c: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter ___ pT1d: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter pT2:Tumor size category 2 ___ pT2a: Tumor size category 2 without ciliary body involvement and extraocular extension ___ pT2b: Tumor size category 2 with ciliary body involvement ___ pT2c: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter ___ pT2d: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter pT3: Tumor size category 3 ___ pT3a: Tumor size category 3 without ciliary body involvement and extraocular extension ___ pT3b: Tumor size category 3 with ciliary body involvement ___ pT3c: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter ___ pT3d: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter pT4: Tumor size category 4 ___ pT4a: Tumor size category 4 without ciliary body involvement and extraocular extension ___ pT4b: Tumor size category 4 with ciliary body involvement ___ pT4c: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter ___ pT4d: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter ___ pT4e: Any tumor size category with extraocular extension more than 5 mm in diameter Regional Lymph Nodes (pN) ___ pNX: Regional lymph nodes cannot be assessed ___ pN0: No regional lymph node metastasis ___ pN1: Regional lymph node metastasis 
CAP Approved
Ophthalmic • Uveal Melanoma UvealMelanoma 3.3.0.
B. Orientation
The orientation of a globe may be determined by identification of extraocular muscle insertions, the optic nerve, and other landmarks, as illustrated in Figure 1 . The terms temporal and nasal are generally used in place of lateral and medial with reference to ocular anatomy. The position of the inferior oblique muscle relative to the optic nerve is most helpful in orienting the globe. The inferior oblique muscle insertion is located temporal (lateral) to the optic nerve on the sclera, and its fibers travel inferonasally from its insertion. The long posterior ciliary artery is often seen as a blue-gray line in the sclera on either side of the optic nerve and marks the horizontal meridian of the globe. Reprinted with permission from WB Saunders Company.
C. Tumor Size
Tumor size has prognostic significance. Many studies of choroidal and ciliary body melanoma have defined small tumors as being less than 10 mm in greatest diameter. 1 More recently, an ongoing study started in 1986, the Collaborative Ocular Melanoma Study 2,3 defined the following size classification based on clinical measurements.
Small tumors # :
Smaller than medium or large tumors defined below Medium tumors:
Greater than or equal to 2.5 mm, less than or equal to 10 mm in height, and less than or equal to 16 mm in basal diameter Large tumors:
Greater than 10 mm in height or Greater than 2 mm in height and greater than16 mm in basal diameter or Greater than 8 mm in height with optic nerve involvement # Small tumors have a more favorable prognosis.
4,5
D. Sectioning the Globe
The globe is generally sectioned in the horizontal or vertical plane, with care to include the pupil and optic nerve in the section to be submitted for microscopic examination. If the mass cannot be included with horizontal or vertical sectioning, the globe is sectioned obliquely to include the tumor, pupil, and optic nerve, as illustrated in Figure 2 . Alternative methods of sectioning have been described.
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Figure 2. The most common methods of sectioning a globe. After transillumination, the tumor base is marked, if possible, and included in the pupil-optic (p-o) nerve section and submitted for processing. If tumor is found in either of the calottes, these may also be submitted for sectioning. The meridian in which the globe was sectioned should be included in the gross description of the pathology report. It is not uncommon to induce an artifactitious retinal detachment while sectioning the globe. This can be minimized by gentle handling and by avoiding a sawing motion with the blade. Reprinted with permission from WB Saunders Company.
E. Histologic Type
The modified Callender classification shown below is used for determining cell type, but has prognostic significance only for tumors of the choroid and ciliary body, not those of the iris, which generally have a benign course. 1, [7] [8] [9] The American Joint Committee on Cancer (AJCC) defined the histopathologic types as follows 
F. TNM Stage Groupings
The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) TNM staging systems for uveal melanoma of the iris, ciliary body, and choroid are shown below. 10 By AJCC/UICC convention, the designation "T" refers to a primary tumor that has not been previously treated. The symbol "p" refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.
Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.
Primary Tumor
All Uveal Melanomas TX Primary tumor cannot be assessed T0
No evidence of primary tumor
Tumor limited to the iris T1a
Tumor limited to the iris not more than 3 clock hours in size T1b
Tumor limited to the iris more than 3 clock hours in size T1c
Tumor limited to the iris with secondary glaucoma T2
Tumor confluent with or extending into the ciliary body, choroid, or both T2a
Tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma T3
Tumor confluent with or extending into the ciliary body, choroid or both, with scleral extension T3a
Tumor confluent with or extending into the ciliary body, choroid or both, with scleral extension and secondary glaucoma T4
Tumor with extrascleral extension T4a
Tumor with extrascleral extension less than or equal to 5 mm in diameter T4b
Tumor with extrascleral extension more than 5 mm in diameter # Iris melanomas originate from, and are predominantly located in, this region of the uvea. If less than half of the tumor volume is located within the iris, the tumor may have originated in the ciliary body, and consideration should be given to classifying it accordingly.
Ciliary Body and Choroid Primary ciliary body and choroidal melanomas are classified according to the 4 tumor size categories below 10 :
T1
Tumor size category 1 T1a
Tumor size category 1 without ciliary body involvement and extraocular extension T1b
Tumor size category 1 with ciliary body involvement T1c
Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter T1d
Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter
T2
Tumor size category 2 T2a
Tumor size category 2 without ciliary body involvement and extraocular extension T2b
Tumor size category 2 with ciliary body involvement T2c
Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter T2d
Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter
T3
Tumor size category 3 T3a
Tumor size category 3 without ciliary body involvement and extraocular extension T3b
Tumor size category 3 with ciliary body involvement T3c
Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter T3d
Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter T4
Tumor size category 4 T4a
Tumor size category 4 without ciliary body involvement and extraocular extension T4b
Tumor size category 4 with ciliary body involvement T4c
Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter T4d
Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter T4e
Any tumor size category with extraocular extension more than 5 mm in diameter It should be noted that regional lymph node involvement is rare in uveal melanoma, but metastasis to the liver and direct extension into the orbit are more common.
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TNM Descriptors
For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.
The "m" suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
The "y" prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).
The "r" prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the "r" prefix: rTNM.
The "a" prefix designates the stage determined at autopsy: aTNM.
Additional Descriptors
Residual Tumor (R) Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.
RX Presence of residual tumor cannot be assessed R0
No residual tumor R1
Microscopic residual tumor R2
Macroscopic residual tumor
For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).
Lymph-Vascular Invasion (LVI) LVI indicates whether microscopic lymph-vascular invasion is identified in the pathology report. LVI includes lymphatic invasion, vascular invasion, or lymph-vascular invasion. By AJCC/UICC convention, LVI does not affect the T category indicating local extent of tumor unless specifically included in the definition of a T category.
G. Other Pathologic Features of Prognostic Significance
Other histologic features with prognostic significance in choroidal and ciliary body melanoma include the number of mitoses in 40 high-powered fields, pigmentation, degree of inflammation, growth pattern (diffuse choroidal melanomas and ring melanomas of the ciliary body have a much less favorable prognosis), location of anterior margin of tumor, degree and patterns of vascularity, blood vessel invasion (both tumor vessels and normal vessels), tumor necrosis, extraocular extension, and optic nerve involvement. 1, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 
